Ultrasound-Responsive Nrf2-Targeting siRNA-Loaded Nanobubbles for Enhancing the Treatment of Melanoma.
drug resistance
melanoma
nanobubbles
nuclear factor erythroid 2-related factor 2 (Nrf2)
small interfering RNA (siRNA)
ultrasound
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
31 Jan 2022
31 Jan 2022
Historique:
received:
25
12
2021
revised:
20
01
2022
accepted:
27
01
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
27
2
2022
Statut:
epublish
Résumé
The siRNA-mediated inhibition of nuclear factor E2-related factor 2 (Nrf2) can be an attractive approach to overcome chemoresistance in various malignant tumors, including melanoma. This work aims at designing a new type of chitosan-shelled nanobubble for the delivery of siRNA against Nrf2 in combination with an ultrasound. A new preparation method based on a water-oil-water (W/O/W) double-emulsion was purposely developed for siRNA encapsulation in aqueous droplets within a nanobubble core. Stable, very small NB formulations were obtained, with sizes of about 100 nm and a positive surface charge. siRNA was efficiently loaded in NBs, reaching an encapsulation efficiency of about 90%. siNrf2-NBs downregulated the target gene in M14 cells, sensitizing the resistant melanoma cells to the cisplatin treatment. The combination with US favored NB cell uptake and transfection efficiency. Based on the results, nanobubbles have shown to be a promising US responsive tool for siRNA delivery, able to overcome chemoresistance in melanoma cancer cells.
Identifiants
pubmed: 35214073
pii: pharmaceutics14020341
doi: 10.3390/pharmaceutics14020341
pmc: PMC8878772
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : University of Turin
ID : ex 60%
Références
Oxid Med Cell Longev. 2016;2016:1958174
pubmed: 26697129
Crit Rev Eukaryot Gene Expr. 2012;22(2):149-60
pubmed: 22856432
Oncol Lett. 2018 Aug;16(2):1959-1966
pubmed: 30008889
Anticancer Res. 2016 Apr;36(4):1497-506
pubmed: 27069125
Drug Discov Today. 2018 Apr;23(4):900-911
pubmed: 29373841
Free Radic Biol Med. 2018 Feb 1;115:447-457
pubmed: 29248722
Nucleic Acid Ther. 2018 Aug;28(4):209-224
pubmed: 29584585
Life Sci. 2021 Jul 15;277:119430
pubmed: 33789144
Anticancer Drugs. 2021 Feb 1;32(2):178-188
pubmed: 32826414
Cell Biosci. 2019 Jun 6;9:45
pubmed: 31183074
J Drug Target. 2017 Nov - Dec;25(9-10):891-898
pubmed: 28817973
Molecules. 2019 Jul 15;24(14):
pubmed: 31311176
Int J Nanomedicine. 2012;7:3309-18
pubmed: 22802689
Mar Drugs. 2019 Jun 25;17(6):
pubmed: 31242678
Cancer Cell. 2018 Jul 9;34(1):21-43
pubmed: 29731393
Oxid Med Cell Longev. 2018 Feb 18;2018:9742154
pubmed: 29670684
J Invest Dermatol. 2014 Feb;134(2):553-556
pubmed: 23938463
Carbohydr Polym. 2021 May 15;260:117809
pubmed: 33712155
Int J Pharm. 2013 Nov 18;456(2):437-45
pubmed: 24008081
Mar Drugs. 2021 Feb 15;19(2):
pubmed: 33672056
Artif Cells Nanomed Biotechnol. 2018 Mar;46(2):274-283
pubmed: 28423924
Front Pharmacol. 2020 Jan 31;10:1650
pubmed: 32082157
Int J Pharm. 2021 Jan 5;592:120033
pubmed: 33144189
Phytomedicine. 2019 Mar 15;56:156-164
pubmed: 30668336
Biomater Sci. 2018 Aug 21;6(9):2426-2439
pubmed: 30040100
Antioxidants (Basel). 2020 Oct 14;9(10):
pubmed: 33066634
Adv Drug Deliv Rev. 2020;154-155:64-78
pubmed: 32768564
Thyroid. 2016 May;26(5):705-16
pubmed: 26906083
Adv Drug Deliv Rev. 2016 Sep 1;104:16-28
pubmed: 26549145
Semin Cell Dev Biol. 2018 Aug;80:50-64
pubmed: 28587975
Clin Cancer Res. 2014 Apr 1;20(7):1965-77
pubmed: 24463458
Nat Commun. 2018 Apr 12;9(1):1410
pubmed: 29650952
Pharmaceutics. 2020 Oct 14;12(10):
pubmed: 33066531
Molecules. 2020 Jun 10;25(11):
pubmed: 32532030
Pharmacol Res. 2008 Nov-Dec;58(5-6):262-70
pubmed: 18838122
Pigment Cell Melanoma Res. 2021 Mar;34(2):268-279
pubmed: 33205526
FASEB J. 2020 Jul;34(7):9713-9726
pubmed: 32497336
Adv Exp Med Biol. 2020;1244:51-68
pubmed: 32301010
Drug Deliv. 2022 Dec;29(1):99-110
pubmed: 34964410
Front Pharmacol. 2019 Sep 11;10:1001
pubmed: 31572183
Ther Deliv. 2016;7(2):117-38
pubmed: 26769397
Cell Death Dis. 2018 Feb 27;9(3):325
pubmed: 29487283
J Acoust Soc Am. 2004 Jul;116(1):272-81
pubmed: 15295987
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Antioxidants (Basel). 2021 Dec 03;10(12):
pubmed: 34943045
Free Radic Biol Med. 2020 Apr;150:125-135
pubmed: 32101771
Biomedicines. 2021 Jul 18;9(7):
pubmed: 34356899
Transl Res. 2019 Dec;214:62-91
pubmed: 31369717
Pharmaceutics. 2021 Oct 04;13(10):
pubmed: 34683910
Adv Drug Deliv Rev. 2019 Apr;144:133-147
pubmed: 31102606
Oncotarget. 2016 Jul 26;7(30):48081-48092
pubmed: 27344172
Biomacromolecules. 2010 Aug 9;11(8):1897-908
pubmed: 20590156
Cell. 2012 Jul 20;150(2):251-63
pubmed: 22817889
Eur J Cancer. 2013 Oct;49(15):3229-41
pubmed: 23870385
Int J Nanomedicine. 2018 Oct 24;13:6791-6807
pubmed: 30425489
Colloids Surf B Biointerfaces. 2013 Apr 1;104:48-53
pubmed: 23298587
Int J Pharm. 2017 Jun 20;525(2):313-333
pubmed: 28416401
Int J Pharm. 2020 Sep 25;587:119676
pubmed: 32738458
Trends Cell Biol. 2020 Jun;30(6):440-451
pubmed: 32303435
J Control Release. 2013 Nov 28;172(1):207-218
pubmed: 23965281
Life Sci. 2021 Jun 15;275:119368
pubmed: 33741417
Cancer Biol Ther. 2019;20(11):1366-1379
pubmed: 31366280
Signal Transduct Target Ther. 2020 Jun 19;5(1):101
pubmed: 32561705
Small. 2019 Sep;15(38):e1901687
pubmed: 31348602
Nanoscale. 2021 Mar 18;13(10):5333-5343
pubmed: 33659972